Skip to main content

KalVista Pharmaceuticals, Inc.

KALVDelisted Jun 11, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001348911

KalVista Pharmaceuticals, Inc. was delisted on Jun 11, 2026; its insiders filed their last Form 4 on Jun 11, 2026; 184 institutions reported holding it in 13F filings for Q1 2026, worth $1.39B in total; no superinvestor held it.

13F holders, Q1 2026

Institutional positions in KalVista Pharmaceuticals, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

KALV is no longer listed, so this page shows Q1 2026. 13F filings for later quarters list far fewer holders.

Institutional holders
184
+25 vs. Q4 2025
Shares held
69.3M
+4.82M (+7.5%) vs. Q4 2025
Total value
$1.39B
+$353.2M (+33.9%) vs. Q4 2025
New holders
41
64 more added
Sold out
16
45 more reduced

3 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q4 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting KALV on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2026: 184 institutions
Q1 2021: 117 institutionsQ2 2021: 110 institutionsQ3 2021: 105 institutionsQ4 2021: 97 institutionsQ1 2022: 89 institutionsQ2 2022: 91 institutionsQ3 2022: 94 institutionsQ4 2022: 91 institutionsQ1 2023: 88 institutionsQ2 2023: 94 institutionsQ3 2023: 101 institutionsQ4 2023: 93 institutionsQ1 2024: 129 institutionsQ2 2024: 119 institutionsQ3 2024: 122 institutionsQ4 2024: 130 institutionsQ1 2025: 128 institutionsQ2 2025: 140 institutionsQ3 2025: 145 institutionsQ4 2025: 162 institutionsQ1 2026: 184 institutionsQ2 2026: 1 institution
Value heldQ1 2026: $1.39B
Q1 2021: $605.1MQ2 2021: $582.7MQ3 2021: $408.2MQ4 2021: $314.6MQ1 2022: $363.9MQ2 2022: $238.7MQ3 2022: $372.0MQ4 2022: $236.2MQ1 2023: $265.0MQ2 2023: $310.1MQ3 2023: $349.2MQ4 2023: $453.0MQ1 2024: $557.2MQ2 2024: $568.2MQ3 2024: $561.0MQ4 2024: $467.4MQ1 2025: $633.7MQ2 2025: $615.5MQ3 2025: $714.0MQ4 2025: $1.08BQ1 2026: $1.39BQ2 2026: $189
Institutions holding KALV and their total value by quarter
QuarterHoldersValue
Q2 20261$189
Q1 2026184$1.39B
Q4 2025162$1.08B
Q3 2025145$714.0M
Q2 2025140$615.5M
Q1 2025128$633.7M
Q4 2024130$467.4M
Q3 2024122$561.0M
Q2 2024119$568.2M
Q1 2024129$557.2M
Q4 202393$453.0M
Q3 2023101$349.2M
Q2 202394$310.1M
Q1 202388$265.0M
Q4 202291$236.2M
Q3 202294$372.0M
Q2 202291$238.7M
Q1 202289$363.9M
Q4 202197$314.6M
Q3 2021105$408.2M
Q2 2021110$582.7M
Q1 2021117$605.1M

Institutions, Q1 2026

Shares, value and share of portfolio for each institution holding KalVista Pharmaceuticals, Inc.; share changes are against Q4 2025.

Institutions holding KALV in Q1 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Group Inc––––Not filed
Sherbrooke Park Advisers LLC––––Not filed
Comerica Bank––––Not filed